BR112021012027A2 - Molécula bifuncional direcionada contra pd-1 humano - Google Patents

Molécula bifuncional direcionada contra pd-1 humano

Info

Publication number
BR112021012027A2
BR112021012027A2 BR112021012027A BR112021012027A BR112021012027A2 BR 112021012027 A2 BR112021012027 A2 BR 112021012027A2 BR 112021012027 A BR112021012027 A BR 112021012027A BR 112021012027 A BR112021012027 A BR 112021012027A BR 112021012027 A2 BR112021012027 A2 BR 112021012027A2
Authority
BR
Brazil
Prior art keywords
bifunctional molecule
against human
targeted against
molecule targeted
bifunctional
Prior art date
Application number
BR112021012027A
Other languages
English (en)
Inventor
Aurore Morello
Caroline Mary
Nicolas Poirier
Virginie Thepenier
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of BR112021012027A2 publication Critical patent/BR112021012027A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

molécula bifuncional direcionada contra pd-1 humano. a presente invenção fornece a molécula bifuncional que compreende um anticorpo anti-hpd-1 humanizado ou fragmento de ligação a antígeno do mesmo ligado a um agente imunoterapêutico capaz de melhorar especificamente a resposta imunológica e usos do mesmo.
BR112021012027A 2018-12-21 2019-12-17 Molécula bifuncional direcionada contra pd-1 humano BR112021012027A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306799 2018-12-21
PCT/EP2019/085781 WO2020127369A1 (en) 2018-12-21 2019-12-17 Bifunctional molecule directed against human pd-1

Publications (1)

Publication Number Publication Date
BR112021012027A2 true BR112021012027A2 (pt) 2021-11-03

Family

ID=65628502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021012027A BR112021012027A2 (pt) 2018-12-21 2019-12-17 Molécula bifuncional direcionada contra pd-1 humano

Country Status (10)

Country Link
US (1) US20220025050A1 (pt)
EP (1) EP3897845A1 (pt)
JP (1) JP2022515223A (pt)
KR (1) KR20210107058A (pt)
CN (1) CN113573782A (pt)
AU (1) AU2019406453A1 (pt)
BR (1) BR112021012027A2 (pt)
CA (1) CA3122899A1 (pt)
IL (1) IL284052A (pt)
WO (1) WO2020127369A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
UY37829A (es) 2017-08-03 2019-01-31 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
ES2941740T3 (es) 2018-01-12 2023-05-25 Amgen Inc Anticuerpos anti-PD-1 y métodos de tratamiento
CA3122526C (en) 2018-12-21 2023-01-03 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
BR112021012037A2 (pt) * 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula anti-pd-1/il-7 bifuncional
EP3898676A1 (en) * 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
WO2021209402A2 (en) * 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
EP4320156A1 (en) * 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CN117460746A (zh) * 2021-06-17 2024-01-26 和铂医药(上海)有限责任公司 靶向pd1和/或ox40的特异性结合蛋白
IL310217A (en) * 2021-07-23 2024-03-01 Akeso Biopharma Inc Pharmacy preparation and use
WO2023046047A1 (zh) * 2021-09-27 2023-03-30 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白质及其应用
WO2023221936A1 (zh) * 2022-05-17 2023-11-23 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
CN116987198B (zh) * 2023-09-28 2023-12-26 军科正源（北京）药物研究有限责任公司 一种靶向人pd-l1的融合蛋白及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5275285A (en) 1992-12-30 1994-01-04 Clegg Industries Business card holder with sound generating microchip
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
AU2002355955A1 (en) 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
PL2066796T3 (pl) 2006-09-20 2011-11-30 Mt Biomethan Gmbh Sposób i urządzenie do separacji metanu i dwutlenku węgla z biogazu
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
UA117294C2 (uk) 2011-02-10 2018-07-10 Рош Глікарт Аг Імунокон'югат
MX2016013686A (es) 2014-04-18 2017-03-31 Univ New York State Res Found Anticuerpos de antigeno anti-tf humanizado.
KR20180004740A (ko) * 2015-04-20 2018-01-12 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
EA201890456A1 (ru) * 2015-08-07 2018-07-31 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
CN105111314B (zh) * 2015-08-13 2019-01-08 成都百世博生物技术有限公司 一种新型融合蛋白、药物组合物及其制备方法和用途
JP6981973B2 (ja) * 2015-10-01 2021-12-17 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
SG11201806120WA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
KR102561356B1 (ko) 2016-09-14 2023-08-03 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
CN108250303B (zh) * 2016-12-19 2023-01-03 南京金斯瑞生物科技有限公司 单域抗体融合蛋白及其应用
EP3571223B1 (en) 2017-01-18 2024-09-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
RS63663B1 (sr) * 2017-04-03 2022-11-30 Hoffmann La Roche Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15
KR20240135066A (ko) 2017-04-13 2024-09-10 사이로파 비.브이. 항-sirp 알파 항체
JP7303802B2 (ja) 2017-09-23 2023-07-05 メモリアル スローン ケタリング キャンサー センター Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
US20210024632A1 (en) 2018-03-05 2021-01-28 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
EP3898676A1 (en) * 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
BR112021012037A2 (pt) * 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula anti-pd-1/il-7 bifuncional

Also Published As

Publication number Publication date
JP2022515223A (ja) 2022-02-17
IL284052A (en) 2021-08-31
US20220025050A1 (en) 2022-01-27
CA3122899A1 (en) 2020-06-25
CN113573782A (zh) 2021-10-29
WO2020127369A1 (en) 2020-06-25
EP3897845A1 (en) 2021-10-27
KR20210107058A (ko) 2021-08-31
AU2019406453A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
BR112021012027A2 (pt) Molécula bifuncional direcionada contra pd-1 humano
CY1124723T1 (el) Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
ECSP20076683A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
ZA201904218B (en) Anti¿ccr7 antibody drug conjugates
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
MX2023011121A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
CL2022000030A1 (es) Moléculas de unión a claudina-6 y usos de las mismas
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
BR112023025433A2 (pt) Anticorpos anti-ccr8 e seus usos
BR112022006620A2 (pt) Anticorpos contra o receptor de poliovírus (pvr) e seus usos
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
CL2021000736A1 (es) Receptor de antígeno quimérico.
MX2018004406A (es) Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UMA EXIGENCIA TECNICA (DESPACHO 6.23) NOTIFICADO NA RPI NO 2790 DE 25/06/2024, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES, UMA VEZ QUE A IMAGEM DO REFERIDO PARECER NAO FOI DISPONIBILIZADA AO PUBLICO.